Platelet activation in type 2 diabetes mellitus

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 8, 2004, Pages 1282-1291

  Ferroni, P ^a   Basili, S ^a   Falco, A ^b   Davì, Giovanni ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Atherosclerosis; Diabetes mellitus; Platelet activation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CALCIUM; CLOPIDOGREL; CYTOKINE; DIPYRIDAMOLE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOBUFEN; ISOPROSTANE; LOW DENSITY LIPOPROTEIN; MEMBRANE LIPID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDOREDUCTASE; PADGEM PROTEIN; PICOTAMIDE; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; THROMBOXANE A2; TICLOPIDINE; TRANSCRIPTION FACTOR; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL FUNCTION; CLINICAL TRIAL; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG TOLERANCE; ENDOTHELIUM; ENDOTHELIUM LESION; GLYCATION; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; IN VIVO STUDY; ISCHEMIA; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PEROXIDATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEINURIA; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE METABOLISM; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANIMALS; ARACHIDONIC ACID; BLOOD GLUCOSE; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HUMANS; LIPID PEROXIDATION; MODELS, BIOLOGICAL; OXIDATIVE STRESS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; THROMBOXANE B2;

EID: 13244274961     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00836.x     Document Type: Review

References (98)

1. Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy. Circulation 2003; 108: 1655-61.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
3. Beckman JA, Creager M, Libby P. Diabetes and atherosclerosis. epidemiology, pathophysiology, and management. J Am Med Assoc 2002; 287: 2570-81.
4. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-42.
5. Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens 2001; 14 475-86.
6. Nishikawa T, Du Edelstein DXL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
7. Pieper GM, Riazul H. Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J Cardiovasc Pharmacol 1997; 30: 528-32.
8. Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 1999; 48: 855-64.
9. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45: 522-30.
10. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
11. Coppola L, Verrazzo G, La Marca C, Ziccardi P, Grassia A, Tirelli A, Giugliano D. Effect of insulin on blood rheology in non-diabetic subjects and in patients with type 2 diabetes mellitus. Diabet Med 1997; 14: 959-63.
12. Davì G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
13. Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract 2000; 50: 1-16.
14. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23: 599-622.
15. Natarajan R, Nadler JL. Lipoxygenases and lipid signaling in vascular cells in diabetes. Front Biosci 2003; 8: s783-95.
16. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease. pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003; 108: 1527-32.
17. Colwell JA, Winocour PD, Halushka PV. Do platelets have anything to do with diabetic microvascular disease? Diabetes 1983; 32 (Suppl. 2): 14-9.
18. Gerrard JM, Stuart MJ, Rao GHR, Steffes MW, Mauer SM, Brown DM, White JG. Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. J Lab Clin Med 1980; 95: 950-8.
19. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
20. Bridges JM, Dalby AM, Millar JHD, Weaver JA. An effect of D-glucose on platelet stickiness. Lancet 1965; 1: 75-7.
21. 2 in non-insulin-dependent diabetes: relationship to vascular complications. Eur J Clin Invest 1984; 14: 83-6.
22. Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-74.
23. Oskarsson HJ, Hofmeyer TG. Platelets from diabetic patients with diabetes mellitus have impaired ability to mediate vasodilation. J Am Coll Cardiol 1996; 27: 1464-70.
24. 2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. Thromb Res 1982; 26: 359-70.
25. Modesti PA, Fortini A, Gensini GF, Vanni D, Prisco D, Abbate R. Human prostacyclin platelet receptors in diabetes mellitus. Thromb Res 1991; 63: 541-8.
26. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-85.
27. Triolo G, Davì G, Giardina E, Cardella F, Meli F, La Grutta A, Shano A, Bompiani GD. Circulating immune complexes and platelet thromboxane synthesis in patients with insulin-dependent (type I) diabetes mellitus. Diabetes 1984; 33: 728-31.
28. Davì G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-9.
29. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-21.
30. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23: 1830-4.
31. Gresele P, Guglielmini G, De Angelis M, Ciferri S, Ciofetta M, Falcinelli E, Lalli C, Ciabattoni G, Davì G, Bolli GB. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013-20.
32. Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia 2001; 44: 188-95.
33. Li Y, Woo W, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Pysiol Heart Circ Pysiol 2001; 280: H1480-9.
34. Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes 1992; 41: 26-31.
35. Tschoepe D, Driesch E, Schwippert B, Nieuwenhuis HK, Gries FA. Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycaemia. Diabetes 1995; 44: 890-4.
36. Watala C, Gwozdzinski K, Pluskota E, Pietrucha T, Walkowiak B, Trojanowski Z, Cierniewski CS. Diabetes mellitus alters the effect of peptide and protein ligands on membrane fluidity of blood platelets. Thromb Haemost 1996; 75: 147-53.
37. Watanabe J, Wohltmann HJ, Klein RL, Colwell JA, Lopes-Virella MF. Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients. Diabetes 1988; 37: 1652-7.
38. Kobayashi K, Watanabe J, Umeda F, Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J 1995; 42: 461-5.
39. Millican SA, Schultz D, Bagga M, Coussons PJ, Muller K, Hunt JV. Glucose-modified low density lipoprotein enhances human monocyte chemotaxis. Free Rad Res 1998; 28: 533-42.
40. Ferretti G, Rabini RA, Bacchetti T, Vignini A, Salvolini E, Ravaglia F, Curatola G, Mazzanti L. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab 2002; 87: 2180-4.
41. Rosenson RS, Lowe GDO. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998; 140: 271-80.
42. Byrne CD. Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype? Atherosclerosis 1999; 145: 1-15.
43. 2-isoprostanes during the oxidative modification of low density lipoprotein. Biochem Biophys Res Commun 1994; 200: 338-43.
44. Falcon C, Pfliegler G, Deckmyn H, Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun 1988; 157: 1190-6.
45. Abrahm DR, Hollingsworth PJ, Smith CB, Jim L, Zucker LB, Sobotka PA, Vinik AI. Decreased alpha 2-adrenergic receptors on platelet membranes from diabetic patients with autonomic neuropathy and orthostatic hypotension. J Clin Endocrinol Metab 1986; 63: 906-12.
46. Udvardy M, Pfliegler G, Rak K. Platelet insulin receptor determination in non-insulin dependent diabetes mellitus. Experientia 1985; 41: 422-3.
47. Trovati M, Anfossi G. Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 2002; 16: 35-40.
48. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003; 115: 37S-41S.
49. Davì G, Guagnano, MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono, C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-14.
50. Ha H, Lee HB. Oxidative stress in diabetic nephropathy: basic and clinical information. Curr Diab Rep 2001; 1: 282-7.
51. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994; 43: 1010-4.
52. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 1995; 44: 1054-8.
53. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997; 17: 2309-15.
54. 2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 2004; 128: 149-63.
55. 2a is not mediated by thromboxane receptor isoforms. J Biol Chem 1996; 271: 14916-24.
56. 2a increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arterioscler Thromb Vasc Biol 1998; 18: 1248-56.
57. Davì G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 2003; 107: 3199-203.
58. Zhang J, Johnston G, Stebler B, Keller ET. Hydrogen peroxide activates NFκB and the interleukin-6 promoter through NFκ B-inducing kinase. Antioxidant Redox Signal 2001; 3: 493-504.
59. De Cristofaro R, Rocca B, Vitacolonna E, Falco A, Marchesani P, Ciabattoni G, Landolfi R, Patrono C, Davì G. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost 2003; 1: 250-6.
60. Hanne HF, Refsgaard LT, Stadtman ER. Modifications of proteins by polyunsaturated fatty acid peroxidation products. Proc Natl Acad Sci USA 2000; 97: 611-6.
61. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-14.
62. Glaser BB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I, Chang RJ, Lin JH, Vilander L, Andrews WH, Light DR. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. J Clin Invest 1992; 90: 2565-73.
63. Martina V, Bruno GA, Trucco F, Zumpano E, Tagliabue M, Di Bisceglie Pescarmona G. Platelet cNOS activity is reduced in patients with IDDM and NIDDM. Thromb Haemost 1998; 79: 520-2.
64. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130: 963-74.
65. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by. UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17: 189-212.
66. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Adjada A, Wadden T. Tumor necrosis factor-α in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998; 83: 2907-10.
67. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-Reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc 2001; 286: 327-34.
68. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 1995; 15: 1114-20.
69. Brandt E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: old players in new games. Immunol Rev 2000; 177: 204-16.
70. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, Weber C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-7.
71. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, Weyrich AS. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485-90.
72. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, Falco A, Cuccurullo F, Davi G. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106: 399-402.
73. Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1: 1897-905.
74. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-8.
75. Mandal S, Sarode R, Dash S, Dash RJ. Hyperaggregation of platelets detected by whole blood platelet aggregometry in newly diagnosed noninsulin-dependent diabetes mellitus. Am J Clin Pathot 1993; 100: 103-7.
76. Kopp HP, Hopmeier P, Schernthaner G. Concentrations of circulating P-selectin are increased in patients with newly diagnosed insulin-dependent diabetes mellitus. Exp Clin Endocrinol Diabetes 1998; 106: 41-4.
77. Davì G, Belvedere M, Vigneri S, Catalano I, Giammarresi C, Roccaforte S, Consoli A, Mezzetti A. Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus. Thromb Haemost 1996; 76: 34-7.
78. Yngen M, Li N, Hjemdahl P, Wallen NH. Insulin enhances platelet activation in vitro. Thromb Res 2001; 104: 85-91.
79. Jennings PE. The potential of gliclazide, a sulphonylurea to influence the oxidative processes within the pathogenesis of diabetic vascular disease. Adv Exp Med Biol 1994; 366: 313-24.
80. Patrono C, Davì G. Antiplatelet agents in the prevention of diabetic vascular complications. Diabet Metabol Rev 1993; 3 177-88.
81. American Diabetes Association. Aspirin therapy in diabetes: position statement. Diabetes Care 2002; 2: S78-9.
82. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006-10.
83. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. New Engl J Med 1989; 321: 129-35.
84. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. J Am Med Assoc 1992; 268: 1292-300.
85. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
86. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br Med J 2002; 324: 71-86.
87. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94.
88. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial: HOT Study Group. Lancet 1998; 351: 1755-62.
89. Colwell JA. Aspirin therapy in diabetes. Diabetes Care 1997; 20: 1767-71.
90. TIMAD Study Group. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990; 108: 1577-83.
91. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625-8.
92. Davì G, Patrono C, Catalano I, Custro N, Giammarresi C, Ganci A, Cosentino F, Notarbartolo A. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. Arterioscler Thromb 1993; 13: 1346-9.
93. Milani M, Longoni A, Maderna M. Effect of picotamide, an antiplatelet agent, on cardiovascular events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Br J Pharmacol 1996; 46: 782-5.
94. Giustina A, Perini P, Desenzani P, Bossoni S, Ianniello P, Milani M, Davì G, Romanelli G. Long-term treatment with the dual anti-thromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes 1998; 47: 423-30.
95. Khajehdehi P, Roozbeh J, Mostafavi H. A comparative randomized and placebo-controlled short term trial of aspirin and dipyridamole for overt type 2 diabetes nephropathy. Scand J Urol Nephrol 2002; 36: 145-8.
96. Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, Weisman HF, Califf RM, Topol EJ. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a Multicenter Trial. EPILOG Investigators. Circulation 1998; 97: 1912-20.
97. Meier-Ewert HK, Nesto RW. Targeting the use of glycoprotein IIb/IIIa antagonists. The diabetic patient. Rev Cardiovasc Med 2002; 3: S20-7.
98. Brandle M, Davidson MB, Schriger DL, Lorber B, Herman WH. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care 2003; 26: 1796-801.